Media recognition & coverage -

Pharmaceutical Technology -
April 22

Enanta Pharmaceuticals gets grant for inhibiting coronavirus replication with compound of formula
Enanta Pharmaceuticals has been granted a patent for compounds that inhibit coronavirus replication. The patent covers pharmaceutical compositions and methods for treating or preventing coronavirus infections. Formula (I) represents the compound structure.

Excerpts:
Human telomerase RT biomarker was a key innovation area identified from patents.

The patent also covers pharmaceutical compositions containing the compound and a method for treating or preventing coronavirus infections in subjects by administering the compound or a combination of compounds.

....the patent involves administering a therapeutically effective amount of the compound to subjects in need, with specific mention of various types of coronaviruses, including SARS-CoV-2. This patent highlights the potential use of the disclosed compounds in combating coronavirus infections, particularly relevant in the current global health scenario.

https://www.pharmaceutical-technology.com/data-insights/enanta-pharmaceuticals-gets-grant-for-inhibiting-coronavirus-replication-with-compound-of-formula-i-2/?utm_source=lgp6-patents-grant&utm_medium=24-295866&utm_campaign=recommended-articles-pi&cf-view

Capisce?

Everything makes CENTS in a potential takeover. I consider the patent holdings are worth their minimal expense - I.E. the patent infringement suit against PFIZER - if it pans out.

Patent Assigned to Enanta Pharmaceuticals, Inc.

Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof

Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
Type: Grant
Filed: May 19, 2021
Date of Patent: April 16, 2024

https://patents.justia.com/assignee/enanta-pharmaceuticals-inc

In certain embodiments, the FXR-mediated disease or condition is cardiovascular disease, atherosclerosis, arteriosclerosis, hypercholesteremia, or hyperlipidemia chronic liver disease, gastrointestinal disease, renal disease, metabolic disease, cancer (i.e., colorectal cancer), or neurological indications such as stroke.

https://patents.justia.com/patent/11958879

Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024
Apr 17, 2024

WATERTOWN, Mass.--(BUSINESS WIRE)--Apr. 17, 2024-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that data from the company’s SPRINT (SARS-Cov-2 PRotease INhibitor Treatment) study of EDP-235 has been accepted for a poster presentation at ESCMID Global 2024 (formerly ECCMID) being held April 27–30 in Barcelona, Spain.

The poster presentation includes primary and post-hoc analyses from the double-blind, placebo-controlled Phase 2 clinical trial of EDP-235, a 3CL protease inhibitor, in non-hospitalized, symptomatic adults with mild or moderate COVID-19 who were not at high risk for severe disease.

Poster Title: “Efficacy and Safety of EDP-235 in Non-Hospitalized Adults with Mild or Moderate COVID-19: Results from the Phase 2 SPRINT Study”
Abstract Number: 02980
Poster Number: PO423
Day: April 27, 2024
Time: 12:00 p.m. CEST / 6:00 a.m. ET
Session Location: Poster Area
Session Title: COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)
Presenter: Scott T. Rottinghaus, M.D., Chief Medical Officer, Enanta Pharmaceuticals, Inc.

The scientific program for ESCMID Global 2024 can be found at https://www.eccmid.org/scientific-programme

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-announces-data-presentation-escmid-global

Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024
Apr 17, 2024

WATERTOWN, Mass.--(BUSINESS WIRE)--Apr. 17, 2024-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that data from the company’s SPRINT (SARS-Cov-2 PRotease INhibitor Treatment) study of EDP-235 has been accepted for a poster presentation at ESCMID Global 2024 (formerly ECCMID) being held April 27–30 in Barcelona, Spain.

The poster presentation includes primary and post-hoc analyses from the double-blind, placebo-controlled Phase 2 clinical trial of EDP-235, a 3CL protease inhibitor, in non-hospitalized, symptomatic adults with mild or moderate COVID-19 who were not at high risk for severe disease.

Poster Title: “Efficacy and Safety of EDP-235 in Non-Hospitalized Adults with Mild or Moderate COVID-19: Results from the Phase 2 SPRINT Study”
Abstract Number: 02980
Poster Number: PO423
Day: April 27, 2024
Time: 12:00 p.m. CEST / 6:00 a.m. ET
Session Location: Poster Area
Session Title: COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)
Presenter: Scott T. Rottinghaus, M.D., Chief Medical Officer, Enanta Pharmaceuticals, Inc.

The scientific program for ESCMID Global 2024 can be found at https://www.eccmid.org/scientific-programme

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-announces-data-presentation-escmid-global

one must be able to describe the thinking and process one takes to create that molecule- if one is to defend their IP.

Thanks for your comments re:patents. Seems ENTA is flush with patents protecting their small molecule discoveries. It would make "cents" to have their discoveries certified & protected by their string of patent attorneys. **Pfizer - watch out!

**

Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026 - APRIL 11

......announced that it has called all $26,350,000 aggregate principal amount of its outstanding 2.625% Convertible Senior Notes Due 2026 (the “Notes”) (CUSIP No. 19459JAA2; ISIN No. US19459JAA25) for redemption on Friday, June 14, 2024 (the “Redemption Date”).

Read more:
https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-pharmaceutical-inc-announces-redemption-outstanding

They keep comin' !

Patents Assigned to Enanta Pharmaceuticals, Inc.
** Benzodiazepine derivatives as RSV inhibitors
Patent number: 11952389
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type: Grant
Filed: May 3, 2022
Date of Patent: April 9, 2024

Patents Assigned to Enanta Pharmaceuticals, Inc.
Benzodiazepine derivatives as RSV inhibitors
Patent number: 11952389
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type: Grant
Filed: May 3, 2022
Date of Patent: April 9, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Brian C. Shook, In Jong Kim, Thomas P. Blaisdell, Jianming Yu, Joseph D. Panarese, Yat Sun Or
Assignee: Enanta Pharmaceuticals, Inc.

** What are Benzodiazepines? Benzodiazepines are depressants that produce sedation and hypnosis, relieve anxiety and muscle spasms, and reduce seizures. The most common benzodiazepines are the prescription drugs Valium®, Xanax®, Halcion®, Ativan®, and Klonopin®.

2 New Patents Assigned to Enanta Pharmaceuticals, Inc. as of April 2

Heterocyclic compounds as anti-viral agents
Patent number: 11945824
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type: Grant
Filed: October 18, 2021
Date of Patent: April 2, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Yat Sun Or, Yong He, Kevin McGrath, Ruichao Shen, Adam Szymaniak, Xuechao Xing, In Jong Kim, Guoqiang Wang

https://patents.justia.com/assignee/enanta-pharmaceuticals-inc

Addendum:

Taking account of the seasonality and predictability of the HRSV and HMPV epidemics, and the severity of infection in high-risk groups such as infants, immunocompromised patients and adults over the age of 65 years, the need for a potent and effective treatment for both HRSV and HMPV is clear. The present invention has identified heterocyclic compounds that are potent inhibitors of both HRSV-A/B and HMPV. The invention includes methods to prepare these compounds, methods for RSV/HMPV cell-based assays and methods of using these compounds to treat HRSV and/or HMPV infections.

https://patents.justia.com/patent/11945824

Antiviral heterocyclic compounds
Patent number: 11945830
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type: Grant
Filed: February 24, 2022
Date of Patent: April 2, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Adam Szymaniak, Jianming Yu, Kevin McGrath, Xiben Li, Tyler J. Mann, Robert Leon, In Jong Kim, Yat Sun Or, Long Nguyen

https://patents.justia.com/assignee/enanta-pharmaceuticals-inc

Addendum:

The present invention has identified compounds that are heterocyclic molecules that are potent against HRSV-AB and HMPV. The invention includes methods to prepare these molecules, methods for the RSV cell-based assay, the HMPV-GFP cell-based assay, the HMPV-TN/1501/A1 cell-based assay, and small-molecules that have potential to treat HRSV/HMPV infection.

https://patents.justia.com/patent/11945830

What is heterocyclic used for?
Heterocyclic Compound - an overview | ScienceDirect Topics
The heterocyclic compounds play an important role in regulating the biochemical process in living system. The compounds may be genetic material, hormones, and enzymes. The common heterocyclic compounds that serve as potential leading drug candidates include amino acid, vitamins, and coenzymes.

Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference - Wed, April 3, 2024 at 8:00 AM EDT

STOUGHTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the 23rd Annual Needham Healthcare Conference being held virtually from April 8-11, 2024.

Details of the event are as follows:
Fireside Chat Date and Time: Wednesday, April 10, 2024, at 3:45 p.m. ET

https://finance.yahoo.com/news/collegium-participate-23rd-annual-needham-120000163.html

PHARMACEUTICAL TECHNOLOGY research news via GlobalData -

March 29, 2024
Enanta Pharmaceuticals gets grant for inhibiting coronavirus replication with compound of formula (i)

Enanta Pharmaceuticals has been granted a patent for compounds that inhibit coronavirus replication. The patent covers pharmaceutical compositions and methods for treating or preventing coronavirus infections. Claim 1 specifically pertains to a compound represented by Formula (I).

Excerpts:
Additionally, the patent includes claims for pharmaceutical compositions comprising the disclosed compound and methods for treating or preventing virus infections, specifically coronavirus infections such as those caused by 229E, NL63, OC43, HKU1, SARS-CoV, or MERS coronavirus.

The patent's claims highlight the compound's versatility in treating various virus infections and respiratory disorders, positioning it as a valuable asset in the field of antiviral and respiratory therapeutics.

Read more:
https://www.pharmaceutical-technology.com/data-insights/enanta-pharmaceuticals-gets-grant-for-inhibiting-coronavirus-replication-with-compound-of-formula-i/

PHARMACEUTICAL TECHNOLOGY research news via GlobalData -

March 29, 2024
Enanta Pharmaceuticals gets grant for inhibiting coronavirus replication with compound of formula (i)

Enanta Pharmaceuticals has been granted a patent for compounds that inhibit coronavirus replication. The patent covers pharmaceutical compositions and methods for treating or preventing coronavirus infections. Claim 1 specifically pertains to a compound represented by Formula (I).

Excerpts:
Additionally, the patent includes claims for pharmaceutical compositions comprising the disclosed compound and methods for treating or preventing virus infections, specifically coronavirus infections such as those caused by 229E, NL63, OC43, HKU1, SARS-CoV, or MERS coronavirus.

The patent's claims highlight the compound's versatility in treating various virus infections and respiratory disorders, positioning it as a valuable asset in the field of antiviral and respiratory therapeutics.

Read more:
https://www.pharmaceutical-technology.com/data-insights/enanta-pharmaceuticals-gets-grant-for-inhibiting-coronavirus-replication-with-compound-of-formula-i/

Since my broker had NO idea - I did some research to prevent my brokerage firm from "borrowing" my ENTA shares for any short sales.

How do I stop short sellers from borrowing my shares?
All you do is to phone your broker and put an order in saying that you wish to place your shares for sale at, for arguments sake, double today's price. As they are 'on order' they cannot be lent out by your broker and in turn you are reducing the amount of 'free shares' out there that can be used for shorting purposes.

As a new, approximately 6 month investor in ENTA, I appreciate the correction. Live & learn - thanks Dew

Might the following new patent be valid for inclusion in the PFIZER suit?

COMBINATIONS OF PHARMACEUTICAL AGENTS AS RSV INHIBITORS
File Date: .................... 2018-09-28.
Pub Date: .....................2024-03-20

Excerpts:

Background of the Invention:
RSV is the leading cause of acute lower respiratory tract infections (ALRI) and affects patients of all ages. The symptoms in adults are usually not severe and are typically analogous to a mild cold. However, in infants and toddlers the virus can cause lower respiratory tract infections including bronchiolitis or pneumonia with many of them requiring hospitalization. Nearly all children have been infected by age 3. There are known high-risk groups that infection with RSV is more likely to progress into the ALRI. Premature infants and/or infants suffering from lung or cardiac disease are at the highest risk to develop ALRI. Additional high-risk groups include the elderly, adults with chronic heart and/or lung disease, stem cell transplant patients and the immunosuppressed.

DETAILED DESCRIPTION OF THE INVENTION:
The compounds of the invention may be administered in a variety of dosage forms. Thus, they can be administered orally, for example as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules. The compounds of the invention may also be administered parenterally, whether subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by infusion techniques. The compounds may also be administered as suppositories.

Read more:
https://www.patentguru.com/EP3687543B1



.

3 Reasons Why Collegium Pharmaceutical (COLL) Is a Great Growth Stock
Zacks Equity Research
Wed, March 13, 2024

EXCERPTS:
Earnings growth is arguably the most important factor, as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors

The company's EPS is expected to grow 15% this year, crushing the industry average, which calls for EPS growth of 14.7%.

Right now, year-over-year cash flow growth for Collegium Pharmaceutical is 27.9%, which is higher than many of its peers. In fact, the rate compares to the industry average of 2.4%.

There have been upward revisions in current-year earnings estimates for Collegium Pharmaceutical. The Zacks Consensus Estimate for the current year has surged 5.2% over the past month.

Bottom Line

While the overall earnings estimate revisions have made Collegium Pharmaceutical a Zacks Rank #1 stock, it has earned itself a Growth Score of A ....

READ MORE:
https://finance.yahoo.com/news/3-reasons-why-collegium-pharmaceutical-164505922.html

Enanta Pharmaceuticals files patent for 17ß-HSD13 inhibitors for treating metabolic disease - March 12

Enanta Pharmaceuticals. has filed a patent for compounds of Formula (I) as 17ß-HSD13 inhibitors for treating metabolic diseases** and liver conditions. The patent claim includes a compound represented by Formula I or its pharmaceutically acceptable salt or ester.

Furthermore, the patent application describes methods for preventing or treating 17ß-HSD13 mediated diseases or conditions in individuals by administering a therapeutically effective amount of the compound. The diseases or conditions targeted include nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), liver cirrhosis, liver fibrosis, and hepatocellular carcinoma (HCC). The use of the compound in the manufacture of medicaments for these specific diseases is also claimed, emphasizing the potential therapeutic applications of the disclosed compound.

https://www.pharmaceutical-technology.com/data-insights/enanta-pharmaceuticals-files-patent-for-17-hsd13-inhibitors-for-treating-metabolic-disease/

**Metabolic disorders: Types, causes, and symptoms -
Examples of metabolic disorders include diabetes, Gaucher's disease, and hemochromatosis. Symptoms can include tiredness, weight loss or gain, and nausea and vomiting. Metabolism is a term that describes the biochemical processes that allow people to grow, reproduce, repair damage, and respond to their environment.

Is this how Amgen started out?

Everything you wanted to know about ENANTA's Patents -

Enanta Pharmaceuticals Patents – Key Insights and Stats
October 25, 2023

Enanta Pharmaceuticals has a total of 1607 patents globally, out of which 619 have been granted. Of these 1607 patents, more than 49% patents are active.

Read more:
https://insights.greyb.com/enanta-pharmaceuticals-patents/

Is this too much? Am I getting carried away or what??

Last current one - for now

December 2023 -

Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
Patent number: 11834436
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Type: Grant
Filed: April 13, 2021
Date of Patent: December 5, 2023
Assignee: Enanta Pharmaceuticals, Inc.

https://patents.justia.com/assignee/enanta-pharmaceuticals-inc
Inventors: Guoqiang Wang, Ruichao Shen, Brett Granger, Jing He, Xuechao Xing, Yong He, Jiang Long, Jun Ma, Bin Wang, Yat Sun Or

In addendum:

Patent Assigned to Enanta Pharmaceuticals, Inc.

Spiropyrrolidine derived antiviral agents
Patent number: 11919910
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

Type: Grant
Filed: November 9, 2022
Date of Patent: March 5, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Guoqiang Wang, Ruichao Shen, Xuechao Xing, Yong He, Matthew C. Rhodes, Yat Sun Or

https://patents.justia.com/assignee/enanta-pharmaceuticals-inc

Read on -They're cornering the market!! Same page -

Spiropyrrolidine derived antiviral agents
Patent number: 11912714
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
Type: Grant
Filed: November 9, 2022
Date of Patent: February 27, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Hui Cao, Wei Li, Xuri Gao, Jiajun Zhang, Xiaowen Peng, Jorden Kass, Ruichao Shen, Guoqiang Wang, Yat Sun Or

Benzodiazepine derivatives as RSV inhibitors
Patent number: 11912695
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type: Grant
Filed: January 13, 2022
Date of Patent: February 27, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Kaicheng Zhu, Kevin McGrath, Solymar Negretti-Emmanuelli, Adam Szymaniak, Jianming Yu, In Jong Kim, Yat Sun Or

Functionalized heterocycles as antiviral agents
Patent number: 11891393
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type: Grant
Filed: November 3, 2021
Date of Patent: February 6, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Joseph Panarese, Dexter Davis, Samuel Bartlett, Katherine Chong, Nathaniel Kenton, Yat Sun Or

Alkyne-containing antiviral agents
Patent number: 11858945
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
Type: Grant
Filed: November 9, 2022
Date of Patent: January 2, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Joseph D. Panarese, Samuel Bartlett, Guoqiang Wang, Yat Sun Or

In addendum:

Patent Assigned to Enanta Pharmaceuticals, Inc.

Spiropyrrolidine derived antiviral agents
Patent number: 11919910
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

Type: Grant
Filed: November 9, 2022
Date of Patent: March 5, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Guoqiang Wang, Ruichao Shen, Xuechao Xing, Yong He, Matthew C. Rhodes, Yat Sun Or

https://patents.justia.com/assignee/enanta-pharmaceuticals-inc

Read on -They're cornering the market!! Same page -

Spiropyrrolidine derived antiviral agents
Patent number: 11912714
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
Type: Grant
Filed: November 9, 2022
Date of Patent: February 27, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Hui Cao, Wei Li, Xuri Gao, Jiajun Zhang, Xiaowen Peng, Jorden Kass, Ruichao Shen, Guoqiang Wang, Yat Sun Or

Benzodiazepine derivatives as RSV inhibitors
Patent number: 11912695
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type: Grant
Filed: January 13, 2022
Date of Patent: February 27, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Kaicheng Zhu, Kevin McGrath, Solymar Negretti-Emmanuelli, Adam Szymaniak, Jianming Yu, In Jong Kim, Yat Sun Or

Functionalized heterocycles as antiviral agents
Patent number: 11891393
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type: Grant
Filed: November 3, 2021
Date of Patent: February 6, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Joseph Panarese, Dexter Davis, Samuel Bartlett, Katherine Chong, Nathaniel Kenton, Yat Sun Or

Alkyne-containing antiviral agents
Patent number: 11858945
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
Type: Grant
Filed: November 9, 2022
Date of Patent: January 2, 2024
Assignee: Enanta Pharmaceuticals, Inc.
Inventors: Joseph D. Panarese, Samuel Bartlett, Guoqiang Wang, Yat Sun Or

Enanta Pharmaceuticals PATENTS new compounds for HBV and HDV - MARCH 9, 2024

Enanta Pharmaceuticals Inc. has disclosed new fused heterobicyclic derivatives reported to be useful for the treatment of hepatitis B virus (HBV) and hepatitis D virus (HDV) infections.

https://www.bioworld.com/topics/520-bioworld-science

Enanta Pharmaceuticals PATENTS new compounds for HBV and HDV - MARCH 9, 2024

Enanta Pharmaceuticals Inc. has disclosed new fused heterobicyclic derivatives reported to be useful for the treatment of hepatitis B virus (HBV) and hepatitis D virus (HDV) infections.

https://www.bioworld.com/topics/520-bioworld-science

The options in question did not expire until 2033, so this is a bullish signal. Thanks DEW.

Several insiders did the same on March 8, 2024. These options would have expired on March 6, 2034.
https://ir.enanta.com/static-files/e961f549-17bf-40f1-8310-7474cbd22802


My next post may be the BULLISH rationale.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Bought by Charles Schwab Investment Management Inc.
Mar 3rd, 2024

Charles Schwab Investment Management Inc. raised its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 5.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 310,139 shares of the specialty pharmaceutical company’s stock after purchasing an additional 14,667 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Collegium Pharmaceutical were worth $6,932,000 at the end of the most recent quarter.

https://www.defenseworld.net/2024/03/03/collegium-pharmaceutical-inc-nasdaqcoll-shares-bought-by-charles-schwab-investment-management-inc.html

Are You Looking for a Top Momentum Pick? Why Collegium Pharmaceutical (COLL) is a Great Choice
March 01, 2024 — 12:00 pm EST

For COLL, shares are up 11.57% over the past week while the Zacks Medical - Drugs industry is down 0.48% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 9.68% compares favorably with the industry's 1.54% performance as well.

While any stock can see a spike in price, it takes a real winner to consistently outperform the market. Over the past quarter, shares of Collegium Pharmaceutical have risen 35.06%, and are up 34.86% in the last year. In comparison, the S&P 500 has only moved 11.77% and 30%, respectively.

Investors should also pay attention to COLL's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. COLL is currently averaging 407,425 shares for the last 20 days.

Earnings Outlook

The Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with COLL.

Over the past two months, 4 earnings estimates moved higher compared to 1 lower for the full year. These revisions helped boost COLL's consensus estimate, increasing from $6.02 to $6.29 in the past 60 days. Looking at the next fiscal year, 3 estimates have moved upwards while there have been no downward revisions in the same time period.

Read more:
https://www.nasdaq.com/articles/are-you-looking-for-a-top-momentum-pick-why-collegium-pharmaceutical-coll-is-a-great

Collegium Pharmaceutical (NASDAQ:COLL) had its price objective increased by analysts at Truist Financial from $37.00 to $40.00 in a note issued to investors on Monday. The firm currently has a "buy" rating on the specialty pharmaceutical company's stock. Truist Financial's price objective points to a potential upside of 10.04% from the company's previous close.

[FLO's price objective -$64 ]

BTW - None of these brokerage houses have taken in account a possible acquisition. Last time that was announced (BDSI) COLL surged $3+ that one day!

Collegium Pharmaceutical Q4: The Beat Goes On

Excerpts:

The company has been paying down debt and repurchasing stock with its impressive operational cash flow.

The shares have gathered momentum since we last gave a "thumbs up" to this name in late October. We take a look at earnings results and update our analysis around this solid small cap

Collegium posted its fourth quarter numbers on February 22nd. The company delivered non-GAAP earnings of $1.58 a share, more than 30 cents a share above estimates. Revenues rose 15.5% on a year-over-year to $149.7 million, slightly above the consensus. For the year, net product revenues came in at $566.8 million, up 22% over FY2022. Belbuca revenue was a core contributor to growth as net product revenues rose 17% to $49.3 million in the quarter. Xtampza ER did even better with a 38% rise from 4Q2022 to $48.5 million.

Since fourth quarter results hit the wires, both Needham ($40 price target) and Piper Sandler ($39 price target) have reiterated Buy ratings on the stock. H.C. Wainwright maintained its Hold rating on the shares.

Verdict:
Collegium Pharmaceutical made $1.29 a share in FY2023 on just under $567 million in sales. The current analyst firm consensus has profits jumping to $3.97 a share in FY2024 and $6.15 a share in FY 2025 on slight increases in revenues. It should be noted these estimates are from just three analyst firms and vary widely for both FY2024 ($2.76 to $6.18 a share) and FY2025 ($3.60 to $8.11 a share).

Even at the low end of estimates, earnings look set to increase at a rapid rate over the next two years. The stock sells at just over 9 times the consensus EPS estimate for this fiscal year. The shares trading near the conversion price of Collegium's convertible debt could be a bit of an overhang.

Read more:
https://seekingalpha.com/article/4673487-collegium-pharmaceutical-q4-the-beat-goes-on

Collegium Pharmaceutical Q4: The Beat Goes On

Excerpts:

The company has been paying down debt and repurchasing stock with its impressive operational cash flow.

The shares have gathered momentum since we last gave a "thumbs up" to this name in late October. We take a look at earnings results and update our analysis around this solid small cap

Collegium posted its fourth quarter numbers on February 22nd. The company delivered non-GAAP earnings of $1.58 a share, more than 30 cents a share above estimates. Revenues rose 15.5% on a year-over-year to $149.7 million, slightly above the consensus. For the year, net product revenues came in at $566.8 million, up 22% over FY2022. Belbuca revenue was a core contributor to growth as net product revenues rose 17% to $49.3 million in the quarter. Xtampza ER did even better with a 38% rise from 4Q2022 to $48.5 million.

Since fourth quarter results hit the wires, both Needham ($40 price target) and Piper Sandler ($39 price target) have reiterated Buy ratings on the stock. H.C. Wainwright maintained its Hold rating on the shares.

Verdict:
Collegium Pharmaceutical made $1.29 a share in FY2023 on just under $567 million in sales. The current analyst firm consensus has profits jumping to $3.97 a share in FY2024 and $6.15 a share in FY2025 on slight increases in revenues. It should be noted these estimates are from just three analyst firms and vary widely for both FY2024 ($2.76 to $6.18 a share) and FY2025 ($3.60 to $8.11 a share).

Even at the low end of estimates, earnings look set to increase at a rapid rate over the next two years. The stock sells at just over 9 times the consensus EPS estimate for this fiscal year. The shares trading near the conversion price of Collegium's convertible debt could be a bit of an overhang.

Read more:
https://seekingalpha.com/article/4673487-collegium-pharmaceutical-q4-the-beat-goes-on

New Career Post -

Senior Supply Chain Planner

RESPONSIBILITIES
[Excerpt]
Proactively and independently manage production schedule, inventory levels, and shipment tracker to ensure materials are ordered, received, tested, and released in a timely fashion to support the integrated business plan

Compensation $102,000—$111,000 USD

Read more:
https://boards.greenhouse.io/collegiumpharma/jobs/4339159006

New Career Posting:

Senior Manager, Market Access Operations

Pay Range
$206,000—$213,000 USD

https://boards.greenhouse.io/collegiumpharma/jobs/4339168006

COLL Earnings Call Transcript:
https://seekingalpha.com/article/4672760-collegium-pharmaceuticals-coll-q4-2023-earnings-call-transcript

COLL Power Point Slide Presentation:
https://ir.collegiumpharma.com/static-files/c4fd20ae-6fec-47fa-b9c0-ba52bc8911e3

On February 22, 2024, Collegium Pharmaceutical Inc (NASDAQ:COLL) released its 8-K filing, announcing record financial results for the fourth quarter and the full year ended December 31, 2023. The specialty pharmaceutical company, known for its abuse-deterrent products and patented DETERx platform technology, reported significant growth in revenue and earnings, surpassing its operational objectives and enhancing shareholder value.

Collegium Pharmaceutical Inc's President and CEO, Joe Ciaffoni, expressed satisfaction with the company's performance, stating,

2023 was a banner year for Collegium Pharmaceutical. We delivered record financial results, achieved our operational objectives and delivered value to shareholders through our share repurchase program."

The company's focus for 2024 is on operational execution, aiming to meet financial guidance and create shareholder value.

Colleen Tupper, Chief Financial Officer, highlighted the company's financial achievements, including record revenue, adjusted EBITDA, and free cash flow. She emphasized the strategic financial management that led to a stronger balance sheet and capital return to shareholders. Tupper anticipates continued growth in 2024, driven by product sales and cost structure leverage.

Financial Performance Analysis
Collegium Pharmaceutical Inc's financial results reflect a robust performance in a competitive industry. The company's record net revenue of $149.7 million for the fourth quarter and $566.8 million for the full year signifies a strong market demand for its products, particularly Belbuca and Xtampza ER. The GAAP net income figures of $31.9 million for the quarter and $48.2 million for the year demonstrate effective cost management and operational efficiency.

The adjusted EBITDA of $104.2 million for the quarter and $367.0 million for the year is a critical metric for investors, as it illustrates the company's profitability and ability to generate cash from operations. The substantial reduction in debt and the successful refinancing of convertible debt are indicative of prudent financial stewardship, which is essential for sustaining growth and weathering market volatility.

Collegium Pharmaceutical Inc's commitment to shareholder returns, as evidenced by the $75.0 million share repurchase, is a testament to the company's confidence in its financial health and long-term prospects. The projected financial guidance for 2024, with net revenue expected to be between $580.0 to $595.0 million and adjusted EBITDA between $380.0 to $395.0 million, sets an optimistic tone for the company's future performance.

In conclusion, Collegium Pharmaceutical Inc's record earnings for the fourth quarter and full year of 2023 reflect a company that is not only thriving in its market niche but is also strategically positioned for continued growth. The company's financial discipline and commitment to shareholder value are likely to appeal to value investors....

Read more:
https://finance.yahoo.com/news/heres-key-metrics-tell-us-000009621.html

CC: Coleen Tupper - Our stock is undervalued. ....Repurchase program of an additional $150M in the next 18 months.

On February 22, 2024, Collegium Pharmaceutical Inc (NASDAQ:COLL) released its 8-K filing, announcing record financial results for the fourth quarter and the full year ended December 31, 2023. The specialty pharmaceutical company, known for its abuse-deterrent products and patented DETERx platform technology, reported significant growth in revenue and earnings, surpassing its operational objectives and enhancing shareholder value.

Collegium Pharmaceutical Inc's President and CEO, Joe Ciaffoni, expressed satisfaction with the company's performance, stating,

2023 was a banner year for Collegium Pharmaceutical. We delivered record financial results, achieved our operational objectives and delivered value to shareholders through our share repurchase program."

The company's focus for 2024 is on operational execution, aiming to meet financial guidance and create shareholder value.

Colleen Tupper, Chief Financial Officer, highlighted the company's financial achievements, including record revenue, adjusted EBITDA, and free cash flow. She emphasized the strategic financial management that led to a stronger balance sheet and capital return to shareholders. Tupper anticipates continued growth in 2024, driven by product sales and cost structure leverage.

Financial Performance Analysis
Collegium Pharmaceutical Inc's financial results reflect a robust performance in a competitive industry. The company's record net revenue of $149.7 million for the fourth quarter and $566.8 million for the full year signifies a strong market demand for its products, particularly Belbuca and Xtampza ER. The GAAP net income figures of $31.9 million for the quarter and $48.2 million for the year demonstrate effective cost management and operational efficiency.

The adjusted EBITDA of $104.2 million for the quarter and $367.0 million for the year is a critical metric for investors, as it illustrates the company's profitability and ability to generate cash from operations. The substantial reduction in debt and the successful refinancing of convertible debt are indicative of prudent financial stewardship, which is essential for sustaining growth and weathering market volatility.

Collegium Pharmaceutical Inc's commitment to shareholder returns, as evidenced by the $75.0 million share repurchase, is a testament to the company's confidence in its financial health and long-term prospects. The projected financial guidance for 2024, with net revenue expected to be between $580.0 to $595.0 million and adjusted EBITDA between $380.0 to $395.0 million, sets an optimistic tone for the company's future performance.

In conclusion, Collegium Pharmaceutical Inc's record earnings for the fourth quarter and full year of 2023 reflect a company that is not only thriving in its market niche but is also strategically positioned for continued growth. The company's financial discipline and commitment to shareholder value are likely to appeal to value investors....

Read more:
https://finance.yahoo.com/news/heres-key-metrics-tell-us-000009621.html

CC: Coleen Tupper - Our stock is undervalued. ....Repurchase program of an additional $150M in the next 18 months.

COLL - ESG REPORT for 2023

https://www.collegiumpharma.com/wp-content/uploads/Collegium-Pharmaceutical_2023-ESG-Report.pdf

New Career Posting other than Sales -

Senior Manager, Total Rewards & HR Operations

https://boards.greenhouse.io/collegiumpharma/jobs/4336527006

1st time salary is stated - competition must be doing such -
$159,837—$176,600 USD

Hello Dew et al - 2 Q's:

1. Does ENTA have a valid case against PFIZER? If so, your analysis?

2. If the previous is positive, at this stage, are you able to handicap the possible odds of a mediated win by ENTA?

TIA

COLL might possibly beat earnings estimate this past Q - nice!

BTW - check out ENTA - bought a large interest recently - upcoming trial results & suit against PFIZER
https://www.enanta.com/

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-files-patent-infringement-suit-against

FORM SC 13 G/A - this A.M. -

Rubric Capital Management LP reports ownership of 2,758,253 shares of Common Stock & 8.46% of COLL common shares.

https://ir.collegiumpharma.com/static-files/d9ec241d-bf09-43b2-add2-0fcba66b8818

Oppenheimer Keeps Their Hold Rating on Enanta Pharmaceuticals (ENTA)

Feb. 9, 2024, 06:58 AM
Oppenheimer analyst Jay Olson maintained a Hold rating on Enanta Pharmaceuticals (ENTA – Research Report) today and set a price target of $17.00. The company’s shares closed yesterday at $12.36.

Olson covers the Healthcare sector, focusing on stocks such as Biogen, Neurocrine, and Viking Therapeutics. According to TipRanks, Olson has an average return of 13.1% and a 43.99% success rate on recommended stocks.

Currently, the analyst consensus on Enanta Pharmaceuticals is a Moderate Buy with an average price target of $19.67, which is a 59.14% upside from current levels. In a report released on February 7, Leerink Partners also maintained a Hold rating on the stock with a $13.00 price target.

https://markets.businessinsider.com/news/stocks/oppenheimer-keeps-their-hold-rating-on-enanta-pharmaceuticals-enta-1033051923

Baird lowered the firm’s price target on Enanta to $26 from $40 and keeps an Outperform rating on the shares. The firm said results largely met expectations, and we are encouraged that management continues to expect to readout data from the RSVPEDs study of zelicapavir in 3Q24, which Baird continues to view as a key catalyst with potential to drive upside potential on the stock.

https://www.tipranks.com/news/the-fly/enanta-price-target-lowered-to-26-from-40-at-baird?utm_source=markets.businessinsider.com&utm_medium=referral